The Eye Center Of Central Pa Optica DME Supplier - Customized Equipment Location: 137 Jpm Rd, Lewisburg, Pennsylvania 17837 Phone: (866) 995-3937 |
Hub's Home Oxygen & Medical Supplie Durable Medical Equipment & Medical Supplies Location: 131 Jpm Rd, Lewisburg, Pennsylvania 17837 Phone: (570) 522-8060 |
Cvs Pharmacy #01604 Durable Medical Equipment & Medical Supplies Location: 350 N 10th St, Lewisburg, Pennsylvania 17837 Phone: (570) 523-3261 |
Walmart Pharmacy 10-1644 Durable Medical Equipment & Medical Supplies Location: 120 Ajk Blvd, Lewisburg, Pennsylvania 17837 Phone: (570) 522-8234 |
Weis Pharmacy 31 Pharmacy Location: 6901 Westbranch Hwy, Lewisburg, Pennsylvania 17837 Phone: (570) 524-5757 |
News Archive
Learning the role of immune-system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS).
One New Jersey nonprofit is bucking the trend of skyrocketing health insurance costs while Congress wrangles with health care reform. Through an entrepreneurial business model, self-insurance and the use of a Voluntary Employee Benefits Association (VEBA), Community Access Unlimited (CAU) has limited increases in health insurance costs to just 3.3 percent in each of the last five years and saved more than $1 million during that time. CAU will have a 0.0 percent increase in 2010 and will expand coverage.
Faced with the inevitability of death, we all wish for good caregiving during the final stage of our lives. A new study from Karolinska Institutet and Ume- University shows that non-pharmacological caregiving at the end of life in specialized palliative care is not as basic as one might believe but is based on complex professional decisions that weave physical, psychosocial and existential dimensions into a functional whole.
Diabetes is the leading reason for kidney failure in the world, resulting in patients requiring dialysis or kidney transplantation. New research has found a cell in the kidney called the podocyte could be the key to understanding why this happens.
Researchers reporting on findings from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial in the UK are recommending that any therapeutic use of REGEN-COV may be best restricted to individuals without detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
› Verified 5 days ago